Meliolabs Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Meliolabs Inc. - overview
Location
Santa Clara, CA, US
Primary Industry
Medical Devices & Equipment
About
Based in California, US, and founded by its CEO, Mridu Sinha, Stephanie Fraley, and Shelley Lawrence, Meliolabs Inc. , operates as a developer of artificial intelligence-powered sequence profiling platform to identify blood-based pathogens using a novel DNA melting technique. In January 2025, Meliolabs Inc. received USD 3.
5 million of grant funding from new investor CARB-X. The company offers an artificial intelligence-based instrument platform that identifies blood-based pathogens. The devices use novel DNA melting techniques to provide end-to-end integrated user workflow serving medical and diagnostic laboratories. The company plans to utilize the January 2025 funding to support the development of its diagnostic platform for detecting neonatal sepsis.
Current Investors
SOSV, CARB-X
Primary Industry
Medical Devices & Equipment
Sub Industries
Diagnostic Equipment, Medical Software
Website
www.melio.tech
Verticals
Artificial Intelligence, HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.